The opening of the 78th session of the UN General Assembly officially took place in New York. The main event of the session is a high-level week, the agenda of which includes meetings on health issues. The Kazakh delegation in this direction was headed by the Minister of Health of the Republic of Kazakhstan Azhar Giniyat.
The delegates also include the Chief State Sanitary Doctor-Vice Minister of Health of the Republic of Kazakhstan, Director of the Department of International Cooperation and Integration of the Ministry of Health of the Republic of Kazakhstan, Advisor to the Minister of Health of the Republic of Kazakhstan and Chairman of the Board of SK-Pharmacia LLP.
During the working trip, the Kazakh delegation met with the regional president of Pfizer, Patrick van der Loo. This meeting is one of the steps in the implementation of the Memorandum of Cooperation with Pfizer, concluded during the working visit of the President of Kazakhstan to New York in September 2022.
In pursuance of the instructions of the Head of State to intensify cooperation with global pharmaceutical corporations, the parties discussed current issues of expanding the presence of the American company in Kazakhstan, including the possibility of jointly implementing projects in the field of vaccine production.
In particular, we are talking about a project for the localization of biotechnological drugs, which provides for contract manufacturing on the basis of existing pharmaceutical production facilities in Kazakhstan. Namely, the production of the 20-valent conjugate pneumococcal vaccine “Prevenar-20” produced by Pfizer (USA, TNC).
To implement the project for localizing the production of the pneumococcal vaccine Prevenar-20, at the beginning of the year, during the visit of the regional head of Pfizer Ozgur Yaziyurt to Astana, a road map was signed with the Ministry of Health of the Republic of Kazakhstan and the Ministry of Foreign Affairs of the Republic of Kazakhstan.
At the end of the meeting, detailed steps for the implementation of joint investment projects planned until 2025 were considered. The parties expressed interest in further strengthening mutually beneficial cooperation and confidence in the successful implementation of joint plans.
For reference:
Pfizer is a leading international biopharmaceutical company with a broad portfolio of innovative pharmaceuticals and vaccines in promising therapeutic areas. The company is present in more than 180 countries, working every day to improve the prevention and treatment of the most serious diseases of our time. Pfizer invests more than $10 billion annually in the research and development of new medicines and vaccines.
.png)
.jpeg)